160 related articles for article (PubMed ID: 34710258)
1. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract][Full Text] [Related]
2. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
[TBL] [Abstract][Full Text] [Related]
3. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED
JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025
[TBL] [Abstract][Full Text] [Related]
5. Value of urinary NMP-22 in patients with renal cell carcinoma.
Ozer G; Altinel M; Kocak B; Yazicioglu A; Gonenc F
Urology; 2002 Oct; 60(4):593-7. PubMed ID: 12385914
[TBL] [Abstract][Full Text] [Related]
6. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
7. Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass.
Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MAS; Diamandis EP; Yousef GM
Am J Pathol; 2019 Dec; 189(12):2366-2376. PubMed ID: 31761032
[TBL] [Abstract][Full Text] [Related]
8. Searching for prognostic biomarkers for small renal masses in the urinary proteome.
Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM
Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112
[TBL] [Abstract][Full Text] [Related]
9. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer.
Morrissey JJ; Mobley J; Figenshau RS; Vetter J; Bhayani S; Kharasch ED
Mayo Clin Proc; 2015 Jan; 90(1):35-42. PubMed ID: 25572193
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M
Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624
[TBL] [Abstract][Full Text] [Related]
11. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
12. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.
Park YH; Baik KD; Lee YJ; Ku JH; Kim HH; Kwak C
BJU Int; 2012 Dec; 110(11 Pt B):E553-8. PubMed ID: 22578274
[TBL] [Abstract][Full Text] [Related]
13. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
[TBL] [Abstract][Full Text] [Related]
15. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
16. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
17. Urinary NMP22 and renal cell carcinoma.
Huang S; Rhee E; Patel H; Park E; Kaswick J
Urology; 2000 Feb; 55(2):227-30. PubMed ID: 10688084
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous Cryoablation of Solitary, Sporadic Renal Cell Carcinoma: Outcome Analysis Based on Clear-Cell versus Papillary Subtypes.
Haddad MM; Schmit GD; Kurup AN; Schmitz JJ; Boorjian SA; Geske J; Thompson RH; Callstrom MR; Atwell TD
J Vasc Interv Radiol; 2018 Aug; 29(8):1122-1126. PubMed ID: 29887184
[TBL] [Abstract][Full Text] [Related]
20. Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence".
Bertolo R; Nicolas M; Garisto J; Magi-Galluzzi C; McKenney JK; Kaouk J
Clin Genitourin Cancer; 2019 Jun; 17(3):209-215.e1. PubMed ID: 31000486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]